High-performance liquid chromatography method for analyzing the antiretroviral agent efavirenz in human plasma

Therapeutic Drug Monitoring

Volumn 21, Issue 3, 1999, Pages 346-350

  Villani, Paola ^a   Pregnolato, Massimo ^a   Banfo, Simona ^a   Rettani, Mauro ^a   Burroni, Daniela ^a   Seminari, Elena ^a   Maserati, Renato ^a   Regazzi, Mario B ^a,b  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Efavirenz; High performance liquid chromatography; HIV infection; Pharmacokinetics

Indexed keywords

ACETONITRILE; ANTIRETROVIRUS AGENT; EFAVIRENZ; SAQUINAVIR; WATER;

ARTICLE; CALIBRATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIQUID LIQUID EXTRACTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REPRODUCIBILITY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STANDARD; VALIDATION PROCESS;

ADMINISTRATION, ORAL; ANTI-HIV AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; OXAZINES; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE INHIBITORS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; ULTRAVIOLET RAYS;

EID: 0033045324     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199906000-00018     Document Type: Article

References (8)

1. Young SD, Britcher SF, Tran LO, et al. L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1995;39:2602-5.
2. Riddler S, Kahn J, Hicks C, et al. Durable clinical anti-HIV-1 activity (72 weeks) and tolerability for efavirenz (DMP 266) in combination with indinavir (IDV) (DMP 266-003. cohort IV). In: Program and abstracts from the 12th World AIDS Conference: June 1998: Geneva, Switzerland, Abstract 12359.
3. Fessel WJ, Haas DW, Delapenha RA, et al. A phase III, double-blind, placebo-controlled, multicenter study to determine the effectiveness and tolerability of the combination of efavirenz (EFV, Sustiva, DMP 266) and indinavir versus indinavir in HIV-infected patients receiving nucleoside analogue (NRTI) therapy at 24 weeks (DMP 266-020). In: Program and abstracts of the 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 22343.
4. Staszewski S, Morales-Ramirez J, Tashima K, et al. A phase III. multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz (EFV)+indinavir (IDV), versus EFV+zidovudine (ZDV)+lamivudine (3TC), versus IDV+ZDV+3TC at 24 weeks (DMP 266-006). In: Program and abstracts from the 12th World AIDS Conference; June 1998; Geneva, Switzerland. Abstract 22336.
5. Fiske WD, Benedek IH, White SJ, et al. Pharmacokinetic interaction between efavirenz (EFV) and nelfinavir mesylate (NFV) in healthy volunteers. In: Program and abstracts from the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, IL. Abstract 349.
6. Fiske WD, Benedek IH, White SJ, et al. Pharmacokinetic interaction between DMP 266 and nelfinavir mesylate (NFV) in healthy volunteers. In: Program and abstracts from the 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 27-30, 1997; Toronto, Ontario. Abstract 1-174.
7. Fiske WD, Benedek IH, Joseph JL, et al. Pharmacokinetic of efavirenz (EFV) and ritonavir (RTV) after multiple oral doses in healthy volunteers. In: Program and abstracts from the 12th World AIDS Conference; June 1998; Geneva, Switzerland. Abstract 42269.
8. Sahai J. Risks and synergies from drug interactions. AIDS 1996;10(suppl 1):21-5.